CA3256001A1 - THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS - Google Patents

THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS

Info

Publication number
CA3256001A1
CA3256001A1 CA3256001A CA3256001A CA3256001A1 CA 3256001 A1 CA3256001 A1 CA 3256001A1 CA 3256001 A CA3256001 A CA 3256001A CA 3256001 A CA3256001 A CA 3256001A CA 3256001 A1 CA3256001 A1 CA 3256001A1
Authority
CA
Canada
Prior art keywords
hydrogen
mmol
reaction
tetrahydroquinolin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3256001A
Other languages
English (en)
French (fr)
Inventor
Mizue OGAWA
Takehiro Takahashi
Kozue Takagaki
Hiroyuki Meguro
Ken Nunettsu Asaba
Masashi Yamamoto
Marina Nogami
Riichiro Tsuji
Naoya Ukegawa
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CA3256001A1 publication Critical patent/CA3256001A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3256001A 2022-06-24 2023-06-23 THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Pending CA3256001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022101476 2022-06-24
JP2022-101476 2022-06-24
PCT/JP2023/023264 WO2023249106A1 (ja) 2022-06-24 2023-06-23 筋萎縮性側索硬化症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
CA3256001A1 true CA3256001A1 (en) 2025-03-18

Family

ID=89380133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3256001A Pending CA3256001A1 (en) 2022-06-24 2023-06-23 THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS

Country Status (8)

Country Link
US (1) US20260083723A1 (https=)
EP (1) EP4545079A1 (https=)
JP (1) JPWO2023249106A1 (https=)
KR (1) KR20250026152A (https=)
CN (1) CN119403554A (https=)
AU (1) AU2023286251A1 (https=)
CA (1) CA3256001A1 (https=)
WO (1) WO2023249106A1 (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
JP3209568B2 (ja) 1991-04-16 2001-09-17 杏林製薬株式会社 新規環状アミノフェニル酢酸誘導体、その製造法及びそれらを有効成分とする免疫応答の修飾剤
KR100236910B1 (ko) 1992-12-14 2000-04-01 김영환 고집적 반도체 기억소자의 메모리셀어레이 제조방법
DE10236910A1 (de) 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
ATE507220T1 (de) 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
EP2733138B1 (en) * 2011-07-15 2016-09-28 Hamari Chemicals, Ltd. Method for producing optically active tetrahydroquinoline
US20140228420A1 (en) 2011-09-05 2014-08-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
CN110372614B (zh) 2019-07-03 2020-09-29 山东师范大学 一种四氢喹喔啉类化合物及制备方法与应用
CN110464727B (zh) 2019-09-06 2025-09-23 山东师范大学 3,4-二氢-2h-苯并-[1,4]恶嗪类药物或其盐在制备抑制铁死亡药物中的应用
IL303307A (en) * 2020-12-25 2023-07-01 Toray Industries Tetrahydroquinoline derivative and its medical use

Also Published As

Publication number Publication date
WO2023249106A1 (ja) 2023-12-28
EP4545079A1 (en) 2025-04-30
AU2023286251A1 (en) 2024-12-05
US20260083723A1 (en) 2026-03-26
CN119403554A (zh) 2025-02-07
JPWO2023249106A1 (https=) 2023-12-28
KR20250026152A (ko) 2025-02-25

Similar Documents

Publication Publication Date Title
US5696136A (en) Method of treating psychosis using azaheterocyclylmethyl
CN102791690B (zh) 作为抗癌药的二取代吡啶衍生物
JP4280067B2 (ja) 治療用ヘテロ環式化合物
US12570639B2 (en) Tetrahydroquinoline derivative and medicinal use thereof
WO2001096308A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
AU2008335709A1 (en) Gamma secretase modulators
JP2004518660A (ja) ４−位においてピペラジン含有部分で置換されたキノリンおよびその窒素化誘導体ならびにその抗菌剤としての使用
EP2393802B1 (en) Dihydroquinolinone derivatives
JP4280068B2 (ja) 治療用クロマン化合物
WO2007038669A9 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
JP2004517129A (ja) 治療用クロモン化合物
WO2015057626A1 (en) QUINOLINYL MODULATORS OF RORyT
JP2005527542A (ja) キノリンおよびアザインドール誘導体およびその５−ｈｔ６リガンドとしての使用
WO2011061318A1 (en) Heterocylic compounds as antagonists of the orexin receptors
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
US20260083723A1 (en) Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis
RU2850795C1 (ru) Производное тетрагидрохинолина и его медицинское применение
TWI917519B (zh) 四氫喹啉衍生物及其醫藥用途
WO2023249105A1 (ja) 薬剤性心筋障害の治療剤又は予防剤
WO1999003833A1 (fr) Derives de piperazine
WO2023249107A1 (ja) 末梢神経障害の治療剤又は予防剤
HK40096343A (zh) 四氢喹啉衍生物及其医药用途

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241120

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250214

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250214

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250318

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250512